Breast Cancer: Clinical Trials

Showing 1 - 50 of 56 trials
Titlesort icon Investigator
Understanding Decision-Making Processes for Undergoing Genetic Testing Among Women with Newly Diagnosed Breast Cancer
[Protocol 11-086]
Robson, Mark, MD
Two Studies of GDC-0032: A Phase I Study of GDC-0032 for Solid Tumors with Increased PI3K Activity, and a Phase II Study of GDC-0032 with Fulvestrant in Patients with Advanced Breast Cancer
[Protocol 13-149]
Dickler, Maura, MD
Risk for Cognitive Decline in Older Women with Breast Cancer
[Protocol 10-079]
Ahles, Tim, PhD
Quality of Life Assessment in Breast Cancer Patients with Radiation-Induced Telangiectasias Treated with Pulsed Dye Laser
[Protocol 13-013]
Lee, Erica, MD
Quality of Life and Patient-Reported Outcomes After Breast Reconstruction Surgery
[Protocol 12-093]
Pusic, Andrea, MD, MHS
Molecular Mechanisms of Clinical Resistance to Anti-HER2 Therapy Among Patients with HER2-Amplified Breast Cancer
[Protocol 06-163]
Chandarlapaty, Sarat, MD, PhD
Mastectomy Reconstruction Outcomes Consortium (MROC) Study
[Protocol 11-175]
Pusic, Andrea, MD, MHS
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmetic Appearance in Patients with Multiple Tumors in One Breast
[Protocol 13-023]
Van Zee, Kimberly, MD
Evaluating the Causes of Cancer in Young Patients
[Protocol 09-068]
Stadler, Zsofia, MD
Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life
[Protocol 10-071]
Blinder, Victoria, MD
EMPOWER Study: Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
[Protocol 10-104]
Oeffinger, Kevin, MD
Development of Group Interventions for Breast Cancer Survivors
[Protocol 12-291]
Lichtenthal, Wendy, PhD
Cognition in Older Breast Cancer Survivors: Influence of Treatment, Genetics, and Smoking History
[Protocol 14-071]
Ahles, Tim, PhD
Clinical Significance of Germline BRCA Mutations
[Protocol 96-051]
Offit, Kenneth, MD
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
[Protocol 12-089]
Tew, William, MD
Assessment of a Customized Computer Program for Reducing Fears of Breast Cancer Recurrence
[Protocol 11-204]
Lichtenthal, Wendy, PhD
Acupuncture for Chronic Lymphedema After Breast Cancer Treatment
[Protocol 12-210]
Cassileth, Barrie, PhD
A Study of Non-Hormonal Vaginal Moisturizer in Hormone Receptor-Positive Postmenopausal Cancer Survivors
[Protocol 12-232]
Carter, Jeanne, PhD
A Study Assessing Varenicline (Chantix) to Treat Tobacco Dependence in Breast Cancer Patients Scheduled for Mastectomy and Reconstructive Surgery
[Protocol 11-136]
Ostroff, Jamie, PhD
A Study Assessing the Use of Dual Handset Phones to Improve Communication with Inpatients Who Have Limited English Proficiency
[Protocol 14-042]
Kumar, Chhavi, MD
A Pilot Study of a Geriatric-Specific Psychoeducational Intervention for Elderly Cancer Patients
[Protocol 09-116]
Roth, Andrew, MD
A Phase III Study of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
[Protocol 11-190]
King, Tari, MD
A Phase III Study of Hormone Therapy with and without Chemotherapy in Patients with HER2-Negative Breast Cancer and 1-3 Positive Lymph Nodes and a Recurrence Score of 25 or Less
[Protocol 12-118]
Lake, Diana, MD
A Phase III Study of BKM120 with Fulvestrant in Postmenopausal Women with Locally Advanced or Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
[Protocol 12-290]
Dickler, Maura, MD
A Phase III Study of Accelerated Whole Breast Radiation Therapy with a Boost versus Standard Whole Breast Radiation with a Boost in Women with Early-Stage Breast Cancer (RTOG 1005)
[Protocol 12-158]
Parhar, Preeti, MD
A Phase III Study Comparing Mometasone Furoate with Eucerin to Treat Radiation-Related Skin Redness and Peeling in Breast Cancer Patients after Mastectomy
[Protocol 13-069]
Olm-Shipman, Molly, RN
A Phase II Study of Weekly Paclitaxel with and without LCL161 in Women with Previously Untreated Triple-Negative Breast Cancer
[Protocol 13-082]
Traina, Tiffany, MD
A Phase II Study of Veliparib plus Temozolomide, Veliparib plus Carboplatin and Paclitaxel, or Carboplatin and Paclitaxel with Placebo in Patients with BRCA Mutations and Metastatic Breast Cancer
[Protocol 12-122]
Robson, Mark, MD
A Phase II Study of SNX-5422 in Patients with Select Advanced HER2 Cancers
[Protocol 13-112]
Voss, Martin, MD
A Phase II Study of Paclitaxel, Trastuzumab, and Pertuzumab for the Treatment of Metastatic HER2-Positive Breast Cancer
[Protocol 10-142]
Dang, Chau, MD
A Phase II Study of Paclitaxel plus Tivozanib or Placebo in Women with Persistent or Recurrent Triple-Negative Breast Cancer
[Protocol 13-047]
Dickler, Maura, MD
A Phase II Study of Multi-Beam Intensity-Modulated Radiation Therapy for Patients with Locally Advanced Breast Cancer Who Had Implant Reconstruction
[Protocol 14-028]
Ho, Alice, MD
A Phase II Study of Fulvestrant Alone or with GDC-0941 or GDC-0980 in Women with Advanced Breast Cancer Resistant to Aromatase Inhibitor Therapy
[Protocol 12-029]
Dickler, Maura, MD
A Phase II Study of Exemestane with and without Enzalutamide in Women with Advanced Hormone Receptor-Positive Breast Cancer
[Protocol 13-257]
Traina, Tiffany, MD
A Phase II Study of Enzalutamide in Women with Triple-Negative Breast Cancer that Contains the Androgen Receptor
[Protocol 13-158]
Traina, Tiffany, MD
A Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide followed by Eribulin Mesylate for the Adjuvant Treatment of Early-Stage Breast Cancer
[Protocol 10-190]
Traina, Tiffany, MD
A Phase II Study of Cabozantinib in Women with Hormone Receptor-Positive Breast Cancer that Spread to the Bone
[Protocol 12-091]
Fornier, Monica, MD
A Phase Ib Study of Oral BGJ398 and BYL719 in Patients with Certain Advanced Solid Tumors
[Protocol 13-246]
Fury, Matthew, MD, PhD
A Phase IB Study of LEE011 and Exemestane with and without Everolimus in Women with Locally Advanced or Metastatic Breast Cancer
[Protocol 13-179]
Modi, Shanu, MD
A Phase I/II Study of Nivolumab Alone and with Ipilimumab in Patients with Advanced or Metastatic Solid Tumors
[Protocol 13-187]
Callahan, Margaret, MD, PhD
A Phase I/II Study of Intrathecal Trastuzumab in Women with HER2-Positive Breast Cancer that Spread to the Spinal Fluid
[Protocol 12-123]
Pentsova, Elena, MD
A Phase I/II Clinical Trial of Temsirolimus plus Neratinib for Subjects with Metastatic HER2-Amplified or Triple-Negative Breast Cancer
[Protocol 10-005]
Chandarlapaty, Sarat, MD, PhD
A Phase I-II Study of Dasatinib plus Paclitaxel in Patients with Metastatic Breast Cancer
[Protocol 08-122]
Fornier, Monica, MD
A Phase I Study of Whole Brain Radiation Therapy plus Sorafenib for Patients with Breast Cancer Brain Metastases
[Protocol 12-046]
Seidman, Andrew, MD
A Phase I Study of Topical Calcitriol (Compound 31543) to Prevent Hair Loss in Women Receiving Paclitaxel for Advanced Breast Cancer
[Protocol 11-205]
Lacouture, Mario, MD
A Phase I Study of Lurbinectedin plus Paclitaxel in Patients with Advanced Solid Tumors
[Protocol 13-170]
Drilon, Alexander, MD
A Phase I Study of HER2/neu DNA Immunization for Patients with Metastatic or High-Risk Breast Cancer
[Protocol 04-101]
Gilewski, Teresa, MD
A Phase I Study of GL-ONC1 for Treating Malignant Pleural Effusion
[Protocol 12-169]
Rusch, Valerie, MD
A Phase I Study of Ganetespib with Paclitaxel and Trastuzumab in Women with Metastatic Breast Cancer
[Protocol 13-168]
Modi, Shanu, MD
A Phase I Study of Enzalutamide (MDV3100) in Patients with Previously Treated Metastatic Breast Cancer
[Protocol 12-155]
Traina, Tiffany, MD